One-stage hybrid coronary revascularization for the treatment of multivessel coronary artery disease— Periprocedural and long-term results from the “HYBRID-COR” feasibility study

• Published in: Frontiers in cardiovascular medicine 2022-10, Vol.9, p.1016255-1016255
• Main Authors: Sanetra, Krzysztof, Buszman, Piotr Paweł, Jankowska-Sanetra, Justyna, Cisowski, Marek, Fil, Wojciech, Gorycki, Bogdan, Bochenek, Andrzej, Slabon-Turska, Monika, Konopko, Marta, Kaźmierczak, Paweł, Gerber, Witold, Milewski, Krzysztof, Buszman, Paweł Eugeniusz
• Format: Article
• Language: English
• Subjects: Cardiovascular Medicine; coronary artery disease; EACAB; hybrid; one-stage; revascularization
• ISSN: 2297-055X; 2297-055X
• DOI: 10.3389/fcvm.2022.1016255

BackgroundThe constant growth of interest in hybrid coronary artery revascularization (HCR) is apparent. Yet, few studies report outcomes of the one-stage HCR. Consequently, the status of such procedures is not adequately supported in clinical guidelines. The aim of this study was to report the safety, feasibility, and long term-outcomes of the one-stage HCR. Methods and resultsPatients were enrolled in the prospective one-stage hybrid coronary revascularization program (HYBRID-COR). They underwent a one-stage hybrid revascularization procedure while on double antiplatelet therapy (DAPT) with Ticagrelor: endoscopic atraumatic coronary artery bypass grafting (EACAB) for revascularization of the left anterior descending (LAD) artery and percutaneous intervention in non-LAD arteries with contemporary drug-eluting stents. The composite primary endpoint included MACCE (major adverse cardiac and cerebrovascular events: death, myocardial infarction, stroke, and repeated revascularization) in long-term observation. The study cohort consisted of 30 patients (68% male) with stable coronary artery disease (26.7%) and unstable angina (73.3%). Procedural success was 100%. No death, myocardial infarction (MI), or stroke were observed in the perioperative period. One patient (3.3%) required chest revision and blood transfusion due to surgical bleeding. Kidney injury was noted in two patients (6.6%). In a long-term follow-up (median; IQR: 4.25; 2.62-4.69 years), two patients (6.6%) underwent repeated revascularization and one patient (3.3%) died due to MI. The overall primary endpoint rate was 9.9%. ConclusionOne-stage hybrid revascularization, on DAPT, is a feasible, safe, and efficient way of achieving complete revascularization in selected patients. The complication rate is low and acceptable. Further randomized trials are required.